查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1874574

全球血液感染检测市场

Bloodstream Infection Testing
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 173 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球血液感染检测市场预计到2030年将达到171亿美元

全球血液传染病检查市场规模在2024年估计为115亿美元，预计到2030年将达到171亿美元，在分析期（2024-2030年）内复合年增长率（CAGR）为6.9%。本报告分析的传统检测细分市场预计将以7.7%的复合年增长率成长，并在分析期结束时达到127亿美元。非传统检测细分市场预计在分析期间将以4.9%的复合年增长率成长。

美国市场规模估计为30亿美元，而中国市场预计将以10.4%的复合年增长率成长。

据估计，2024年美国血液传染病检查市场规模将达30亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到42亿美元，在2024年至2030年的分析期间内，复合年增长率（CAGR）将达到10.4%。其他值得关注的区域市场分析包括日本和加拿大，预计在分析期间内，这两个国家的复合年增长率分别为3.4%和6.3%。在欧洲，德国预计将以约4.2%的复合年增长率成长。

全球血液感染检测市场－主要趋势与驱动因素概述

为什么血液传染传染病检查是医学诊断的基础

血流感染 (BSI) 检测在医学诊断中发挥着至关重要的作用，因为它对于早期发现和治疗败血症至关重要。脓毒症是一种危及生命的疾病，由身体对感染疾病的过度免疫反应所引起。 BSI 由多种病原体引起，包括细菌、真菌和病毒，快速识别这些病原体对于预防其发展为重症脓毒症或败血性休克至关重要，而这两种疾病均与高死亡率相关。及时进行 BSI 检测有助于医护人员给予适当的抗菌治疗，从而降低併发症风险并改善患者预后。作为医院感染控制的基石，BSI 检测对于预防感染传播也至关重要，尤其是在加护病房，因为那里的患者最为脆弱。

技术创新如何改变血液感染检测？

血液传染传染病检查领域正因技术的快速发展而发生变革，诊断的速度、准确性和整体性均显着提升。传统的血液培养方法需要数天才能出结果，如今正被聚合酵素链锁反应(PCR)、质谱分析和次世代定序(NGS) 等先进的分子诊断技术所补充或取代。这些技术能够快速鑑定病原体（通常在数小时内），从而实现更早、更有针对性的治疗性介入。此外，照护现场检测 (POC) 设备的出现使血流感染 (BSI) 的诊断更加便捷，有助于在急诊和远端医疗环境中更快地做出决策。人工智慧 (AI) 和机器学习演算法在诊断平台中的应用也提高了对复杂数据的解读能力，从而带来更准确的诊断和更完善的患者管理。

影响血液传染传染病检查市场的挑战和监管压力有哪些？

血液传染传染病检查市场受到许多挑战和监管压力的复杂影响。其中一个关键挑战是需要高灵敏度和高特异性的检测方法，以准确识别包括难以培养或检测的病原体在内的多种病原体。这种需求推动了对诊断技术研发和创新的大量投资。同时，美国食品药物管理局（FDA）和欧洲药品管理局（EMA）等监管机构对新检测方法的核准制定了严格的标准，以确保只有最有效、最安全的诊断方法才能进入市场。虽然这些法规对于维护血流感染（BSI）检测的品质和可靠性至关重要，但也为中小企业和Start-Ups公司设置了市场准入壁垒。此外，人们对抗生素抗药性的日益关注也促使人们开发出不仅能够识别病原体，还能提供抗生素敏感性资讯的BSI检测方法，从而製定更有效的治疗方案。

推动血液传染病检查市场成长的关键因素有哪些？

血液传染病检查市场的成长受多种因素驱动，包括医院获得性感染（HAI）发病率的上升和抗药性病原体的日益流行，这些因素增加了对快速准确诊断的需求。败血症的全球负担，尤其是在老化社会和免疫力缺乏患者群体中，也推动了对先进血流感染（BSI）检测解决方案的需求。此外，个人化医疗的兴起以及对病原体特异性精准治疗方法的需求，正在推动BSI检测中尖端分子诊断技术的应用。自动化和高通量检测平台等技术的进步，提高了诊断速度，这对于有效管理BSI至关重要。此外，新兴市场医疗基础设施的不断改善以及医护人员和公众对败血症认识的提高，也促进了市场成长。随着全球医疗系统持续重视感染控制和抗菌药物管理，对高效可靠的血流感染检测的需求预计将会增加，从而推动这一重要细分市场的进一步创新和扩张。

部分：

依技术分类（常规测试、非常规测试）

受访公司范例

  • Abbott Laboratories
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific, Inc.

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，改变您分析市场和竞争情报的方式。

Global Industry Analysts 并没有查询通用的 LLM 或产业专用的SLM，而是建立了一个由世界各地领域专家精心策划的内容库，包括影片文字稿、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

我们最新发布的报告纳入了关税对区域市场的影响，正如全球产业分析师预测的那样，关税将改变企业的竞争地位，而企业的竞争地位将取决于其总部所在地、製造地以及进出口（成品和OEM产品）。这种复杂多变的市场现实将透过微观和宏观市场动态影响竞争对手，包括销货成本增加、盈利下降以及供应链重组。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 亚太其他地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP10753

Global Bloodstream Infection Testing Market to Reach US$17.1 Billion by 2030

The global market for Bloodstream Infection Testing estimated at US$11.5 Billion in the year 2024, is expected to reach US$17.1 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Conventional Testing, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$12.7 Billion by the end of the analysis period. Growth in the Non-Conventional Testing segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 10.4% CAGR

The Bloodstream Infection Testing market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 10.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Bloodstream Infection Testing Market - Key Trends and Drivers Summarized

Why Is Bloodstream Infection Testing a Cornerstone in Medical Diagnostics?

Bloodstream infection (BSI) testing plays a pivotal role in medical diagnostics, as it is crucial for the early detection and treatment of sepsis, a life-threatening condition caused by an overwhelming immune response to infection. BSIs can result from a variety of pathogens, including bacteria, fungi, and viruses, and their rapid identification is essential to prevent the progression to severe sepsis or septic shock, both of which are associated with high mortality rates. Timely BSI testing allows healthcare providers to administer appropriate antimicrobial therapies, thereby reducing the risk of complications and improving patient outcomes. As a cornerstone of infection control in hospitals, BSI testing is also vital in preventing the spread of infections, particularly in critical care units where patients are most vulnerable.

How Are Technological Innovations Transforming Bloodstream Infection Testing?

The landscape of bloodstream infection testing is being transformed by rapid advancements in technology, which are enhancing the speed, accuracy, and comprehensiveness of diagnostics. Traditional blood culture methods, which can take days to deliver results, are being supplemented or replaced by advanced molecular diagnostic techniques such as polymerase chain reaction (PCR), mass spectrometry, and next-generation sequencing (NGS). These technologies enable the rapid identification of pathogens, often within hours, allowing for earlier and more targeted treatment interventions. Additionally, the advent of point-of-care (POC) testing devices is bringing BSI diagnostics closer to the patient, facilitating quicker decision-making in emergency and remote healthcare settings. The integration of artificial intelligence (AI) and machine learning algorithms into diagnostic platforms is also enhancing the interpretation of complex data, leading to more accurate diagnoses and better patient management.

What Challenges and Regulatory Pressures Are Shaping the Bloodstream Infection Testing Market?

The bloodstream infection testing market is shaped by a complex interplay of challenges and regulatory pressures. One of the primary challenges is the need for highly sensitive and specific tests that can accurately identify a wide range of pathogens, including those that are difficult to culture or detect. This demand has led to significant investment in research and development, driving innovation in diagnostic technologies. At the same time, regulatory bodies such as the FDA and the European Medicines Agency impose stringent standards for the approval of new testing methods, ensuring that only the most effective and safe diagnostics are brought to market. These regulations are critical for maintaining the quality and reliability of BSI testing but also pose barriers to market entry for smaller companies and startups. Additionally, the growing concern over antibiotic resistance is influencing the development of BSI tests that can provide not only pathogen identification but also insights into antibiotic susceptibility, thereby guiding more effective treatment decisions.

What Are the Key Drivers Behind the Growth of the Bloodstream Infection Testing Market?

The growth in the bloodstream infection testing market is driven by several factors, including the rising incidence of hospital-acquired infections (HAIs) and the increasing prevalence of drug-resistant pathogens, which heighten the need for rapid and accurate diagnostics. The global burden of sepsis, particularly in aging populations and immunocompromised patients, is also fueling demand for advanced BSI testing solutions. Furthermore, the shift towards personalized medicine and the need for precise, pathogen-specific treatment regimens are driving the adoption of cutting-edge molecular diagnostics in BSI testing. Technological advancements, such as the development of automated and high-throughput testing platforms, are reducing the time to diagnosis, which is critical in managing BSIs effectively. Additionally, the expansion of healthcare infrastructure in emerging markets and the increasing awareness of sepsis among healthcare providers and the general public are contributing to market growth. As healthcare systems worldwide continue to prioritize infection control and antimicrobial stewardship, the demand for efficient and reliable bloodstream infection testing is expected to rise, driving further innovation and expansion in this critical market segment.

SCOPE OF STUDY:

The report analyzes the Bloodstream Infection Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Conventional Testing, Non-Conventional Testing)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Bloodstream Infection Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Incidence of Sepsis Propels Demand for Bloodstream Infection Testing
    • Rising Healthcare-Associated Infections Expand the Addressable Market Opportunity
    • Technological Innovations in Rapid Diagnostics Drive Market Growth
    • Adoption of Point-of-Care Testing Strengthens the Business Case for Faster Diagnostics
    • Increasing Antimicrobial Resistance Throws the Spotlight on Early Detection
    • Rising Awareness of Bloodstream Infections Spurs Market Expansion
    • Advancements in Molecular Testing Techniques Sustain Market Growth
    • Shift Towards Personalized Medicine Expands Market Potential
    • Here's the Story: How the Need for Rapid, Accurate Results Generates Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bloodstream Infection Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bloodstream Infection Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Bloodstream Infection Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Conventional Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Conventional Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Conventional Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Conventional Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Conventional Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Conventional Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: USA 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: Canada 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • JAPAN
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: Japan 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • CHINA
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: China 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • EUROPE
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Bloodstream Infection Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Europe 15-Year Perspective for Bloodstream Infection Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • FRANCE
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: France 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • GERMANY
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Germany 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Italy 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: UK 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Spain 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Russia 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Bloodstream Infection Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 15-Year Perspective for Bloodstream Infection Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Australia 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • INDIA
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: India 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: South Korea 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Bloodstream Infection Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Latin America 15-Year Perspective for Bloodstream Infection Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Latin America 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Argentina 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Brazil 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Mexico 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Bloodstream Infection Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Middle East 15-Year Perspective for Bloodstream Infection Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Middle East 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Iran 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Israel 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UAE 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • AFRICA
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Africa 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030

IV. COMPETITION